Domestic drug firm Caplin Point Laboratories has signed a license and distribution pact with UK-based Cycle Pharmaceuticals to develop and manufacture specific pharma products.
The abbreviated new drug application (ANDA) and marketing rights of the products for the US market will be with the Cycle Pharma.
"A license and distribution agreement has been made and entered by and between Caplin Point Laboratories Ltd India and Cycle Pharmaceuticals Ltd, a Ltd Company having its principal offices at Cambridge, UK," Caplin said in a filing to the BSE, suggest agencies.
Reportedly, as per the pact, Caplin will be responsible of developing and manufacturing identified liquid injectable products, whereas Cycle Pharmaceuticals will hold this ANDA and commercialise the same in USA.
Meanwhile, Chennai based Caplin informed agencies, "This is a product specific agreement for United States of America. Currently one product is featuring in the contract.”
The company has received milestone payment for one product and the product development cum dossier preparation have just commenced, it added.
Cycle Pharmaceuticals is a niche global firm with sharp focus on key geographies like the US and Europe.
